Introduction
============

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases secreted as latent proenzymes into the extracellular space. Once activated, MMPs are capable of degrading a variety of extracellular matrix (ECM) components.[@b1-jir-8-193] Soluble MMPs, particularly MMP2 and MMP9, are major modulators of fetal membrane integrity throughout gestation and are responsible for membrane rupture at the onset of labor.[@b2-jir-8-193] Membrane type 1 MMP (MT1-MMP, also known as MMP14) is synthesized as an inactive 63 kDa latent enzyme, which is transported to the cell membrane where it is cleaved into the active 57 kDa form.[@b3-jir-8-193] In addition to degrading ECM components, MT1-MMP is a potent physiological activator of soluble MMPs. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of MMPs and regulate their activation by binding in a 1:1 stoichiometry;[@b4-jir-8-193] shifting the balance between TIMPs and active MMPs results in excessive proteolytic activity.[@b5-jir-8-193]

Latent MMP2 (pro-MMP2) is secreted as a 72 kDa proenzyme, and is not readily activated into its active 68 kDa form by general proteolytic cleavage.[@b6-jir-8-193]--[@b10-jir-8-193] Instead, activation is mediated at the cell surface via a series of reactions involving MT1-MMP and TIMP2.[@b4-jir-8-193] A pro-MMP2/TIMP2 complex is formed via the C-terminal of both proteins, leaving the inhibitory N-terminal of TIMP2 free to bind MT1-MMP at the cell surface. Once at the cell surface, the pro-MMP2 is activated by a second MT1-MMP, which is free of TIMPs. Alternatively, if TIMP2 is already inhibiting MT1-MMP, this complex may act as a receptor for pro-MMP2.[@b4-jir-8-193],[@b5-jir-8-193],[@b11-jir-8-193]

The regulation of MT1-MMP in human placenta is not well understood. MT1-MMP has previously been detected in fetal membranes collected at term gestation from non-laboring cesarean section (CS) deliveries, and from normal vaginal deliveries with the spontaneous onset of labor (spontaneous vaginal delivery \[SVD\]). Fortunato et al have reported that MT1-MMP mRNA and protein were present in the fetal membranes and that no differences were detected following culture with lipopolysaccharide (LPS), suggesting constitutive expression of this MMP in the fetal membranes.[@b12-jir-8-193]

There is conflicting information about the role of MMP2 in fetal membrane rupture at term gestation. MMP2 has been reported to be constitutively expressed in fetal membranes throughout gestation.[@b13-jir-8-193],[@b14-jir-8-193] However, it has more recently been shown to increase with gestational age in amnion, with significantly increased levels at term labor.[@b15-jir-8-193] MMP2 has also been implicated in preterm premature rupture of the fetal membranes (pPROM)[@b16-jir-8-193] and is increased in the presence of LPS.[@b17-jir-8-193] TIMP2 protein increases with advancing gestational age, and decreases with preterm and term labor, pPROM, and in the presence of intra-amniotic infection.[@b18-jir-8-193] Furthermore, TIMP2 protein is decreased in cultured fetal membranes exposed to LPS.[@b17-jir-8-193],[@b18-jir-8-193]

Epigenetic regulation refers to modifications to DNA and chromatin that result in heritable changes in gene expression independent of the genetic sequence and include DNA methylation and histone modifications.[@b19-jir-8-193] DNA methylation refers to the addition of a methyl group to the cytosine ring in DNA in the context of a CpG dinucleotide, to form methyl cytosine (5-mC). The silencing of TIMP genes via promoter methylation is a hallmark of cancer development, and the MT1-MMP/MMP2/TIMP2 axis is regulated by a combination of DNA methylation and histone modifications in cancer cells.[@b20-jir-8-193]

In the current study, we hypothesize that MT1-MMP, MMP2, and TIMP2 are regulated by DNA methylation in human term placenta and that aberrant methylation leading to altered gene expression may contribute to fetal membrane rupture.

Materials and methods
=====================

Tissue collection and explant system
------------------------------------

The present study was designed in accordance with the principles set out in the Declaration of Helsinki. Ethical approval for the study was obtained from Northern X Regional Ethics Committee (NTX/10/07/062), and tissues were collected following written informed consent. Villous placental tissues were collected from women at term with uncomplicated, singleton pregnancies (38--40 weeks gestation) following elective CS (mean maternal age 35 years, mean gestational age 38 weeks). Tissue culture protocol including doses and length of treatments were based on a previously published in vitro tissue explant system,[@b21-jir-8-193]--[@b23-jir-8-193] with modifications.

Samples of villous tissue were taken randomly across the placenta from midsections of cotyledons (halfway between the maternal and fetal sides). Large vessels were removed using blunt dissection and leaving only villous tissue, which was further dissected into 20 mg pieces. Villous explants were plated separately (six pieces per well) and were equilibrated for 24 hours in Dulbecco's Modified Eagle's Medium (DMEM)/F12 containing L-glutamate (Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and 1% antibiotic solution (final concentrations 100 U/mL penicillin and 100 μg streptomycin; Thermo Fisher Scientific) in a humidified atmosphere of 5% CO~2~ and 8% O~2~.

After equilibration, tissues were washed and media were replaced with DMEM/F12 supplemented with 0.1% bovine gamma globulin (Sigma-Aldrich Co, St Louis, MO, USA) containing 5 μM 5-AZA-2′-deoxycytidine (AZA; Sigma-Aldrich Co) or dimethyl sulfoxide (DMSO, a vehicle control; Sigma-Aldrich Co). Following 48 hours culture, tissues were extensively washed in sterile phosphate-buffered saline (PBS), and tissues were further incubated in the presence or absence of 5 μg/mL LPS and *Escherichia coli* 055.B5 (Sigma-Aldrich Co). Tissues were cultured with LPS to determine if an inflammatory response induced changes in TIMP1 expression and/or DNA methylation. Culture was terminated at 24 hours and 48 hours post-LPS treatment; tissues were snap-frozen, and conditioned media were reserved. Tissues and media samples were stored at −80°C and −20°C, respectively.

RNA extraction and quantitative real-time polymerase chain reaction
-------------------------------------------------------------------

Total RNA was isolated from tissues using Trizol (Thermo Fisher Scientific) according to the manufacturer's instructions. RNA concentrations were quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). Following DNase treatment, reverse transcription and cDNA synthesis were performed using a Transcriptor First Strand cDNA Synthesis Kit (Hoffman-La Roche Ltd, Basel, Switzerland) according to the manufacturer's instructions using 1 μg of total RNA for each preparation. The resulting cDNA was stored at −20°C until required.

*MT1-MMP, MMP2*, and *TIMP2* mRNA expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) using the LightCycler^®^ 480 and LightCycler 480 SYBR^®^ Green Master Mix (Hoffman-La Roche Ltd). Gene-specific primers used are detailed in [Table 1](#t1-jir-8-193){ref-type="table"}. *RPLPO* and *RPL13a* were used as endogenous controls to normalize gene expression, and the average transcript quantity in treated tissue explants was calculated using the delta-delta CT method.[@b24-jir-8-193]

Western blotting
----------------

Western blotting was performed on whole cell lysates using rabbit monoclonal anti-MT1-MMP antibody (1:1,000 dilution, product number ab51074, Abcam, Cambridge, UK). Proteins were separated by weight by sodium dodecyl sulfate polyacrylamide gel electrophoresis using 4%--12% Bis-Tris gels (Thermo Fisher Scientific), and were transferred onto polyvinylidene fluoride membrane. Following pre-incubation with a blocking solution, membranes were incubated in primary antibody overnight. The membranes were then extensively washed, incubated in horseradish peroxidase (HRP)-conjugated secondary antibody (1:10,000 dilution, product number A5045; Sigma Aldrich Co), and were visualized using Pierce Super-Signal^®^ West Dura Extended Duration Substrate (Thermo Fisher Scientific). Relative protein levels were obtained using densitometric quantification within the linear range (Quantity One^®^ software; Bio-Rad Laboratories Inc., Hercules, CA, USA) and were normalized to β-actin.

Gelatin zymography
------------------

MMP2 activity was measured in conditioned media from placental explant cultures using gelatin zymography. Samples were separated by electrophoresis (125 V for 90 minutes) on Novex^®^ 10% gelatin zymogram gels (Thermo Fisher Scientific). Gels were incubated in denaturing buffer for 30 minutes, and then in developing buffer overnight at 37°C. Gels were stained in a solution containing 0.3% coomassie blue, after which areas on the gel that had been degraded appeared as clear bands against a dark background. Molecular weights were determined using a standard of conditioned media from HT-1080 human fibrosarcoma cells, which constitutively express MMP2 and MMP9. Gels were scanned with a GS-800 calibrated densitometer (Bio-Rad Laboratories Inc.) and were analyzed using Quantity One software (Bio-Rad Laboratories Inc.).

Enzyme-linked immunosorbent assay
---------------------------------

Total TIMP2 protein in conditioned media from tissue explant experiments was measured using a human TIMP2 DuoSet^®^ enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems Inc., Minneapolis, MN, USA) according to the manufacturer's instructions. Optical density was read at 450 nm and was corrected with 540 nm on a Synergy™ 2 multimode plate reader (BioTek, Winooski, VT, USA). Levels of secreted TIMP2 were normalized with respect to the total protein content as measured by microplate bicinchoninic assay protein assay kit (Thermo Fisher Scientific).

DNA extraction and methylation analysis of *MT1-MMP* promoter
-------------------------------------------------------------

Genomic DNA was extracted from tissues using the QiaAMP DNA extraction kit (Qiagen NV, Venlo, the Netherlands) as per manufacturer's instructions and quantified using a NanoDrop ND-1000 spectrophotometer.

Methylation analysis using the Sequenom™ EpiTyper^®^ MassARRAY platform was undertaken by the Australian Genome Research Facility (AGRF). Primer sets to cover two regions (A and B) of the major CpG island in the *MT1-MMP* promoter region were designed in-house by AGRF. Region A covered 30 CpG sites and region B covered 38 CpG sites. Primers used for Sequenom analysis are detailed in [Table 2](#t2-jir-8-193){ref-type="table"}. Methylation analysis was carried out on bisulfite-converted DNA using 200 ng for each preparation. Methylation levels for each CpG unit were expressed as a percentage, which was calculated from the ratio of mass signals between methylated and nonmethylated DNA in each sample.

Chromatin accessibility assay
-----------------------------

Chromatin assembly of treated villous explant tissues was carried out using the EpiQuik chromatin accessibility assay kit (Epigentek, Farmingdale, NY, USA). Chromatin was isolated from tissues and treated with a nuclease (Nse) mix. DNA was then isolated and amplified using quantitative PCR and gene-specific primers for *MT1-MMP* ([Table 1](#t1-jir-8-193){ref-type="table"}). Control primers were provided to determine the successful digestion of the chromatin. The fold enrichment (FE) was calculated by the ratio of amplification efficiency of the Nse-treated DNA sample over that of the control sample not treated with nuclease (No-Nse): $$(\text{FE} = 2^{(\text{Nse}\ \text{CT} - \text{no-Nse}\ \text{CT})} \times 100\%)$$

Changes in chromatin structure in treated tissues were identified by the degree of Ct shift between digested and undigested samples. DNA in heterochromatin was inaccessible to the nucleases, resulting in insignificant Ct shifts between digested and undigested (control) samples, whereas DNA in euchromatin was accessible to nucleases, resulting in a large Ct shift.

Statistical analysis
--------------------

Statistical analyses were performed using GraphPad Prism version 6.0 for Windows (GraphPad Software Inc., La Jolla, CA, USA). Comparisons between tissues collected from CS and SVD pregnancies were carried out using the Mann--Whitney *U* test. One-way analysis of variance was used for explant experiments and if significantly different (α=0.05), post hoc multiple comparisons using Dunn's test were performed for comparison to time-matched controls. Values are presented as mean±standard error of the mean (SEM).

Results
=======

Effect of AZA and LPS treatments on MT1-MMP mRNA and protein
------------------------------------------------------------

*MT1-MMP* mRNA was significantly increased in placental explants pretreated with AZA and then stimulated with LPS for 24 hours or 48 hours compared to controls. Significant increase was also observed in explants following LPS stimulation alone for 48 hours ([Figure 1A](#f1-jir-8-193){ref-type="fig"}). MT1-MMP protein was significantly increased in placental explants pre-treated with AZA and then stimulated with LPS for 24 hours and 48 hours, and treated with LPS alone for 24 hours ([Figure 1B](#f1-jir-8-193){ref-type="fig"}).

Effect of AZA and LPS treatments on MMP2 mRNA and protein secretion
-------------------------------------------------------------------

*MMP2* mRNA expression was not altered by AZA or LPS treatment alone or in combination in any tissue (data not shown). MMP2 activity, however, was significantly increased in the culture media from placental explants pre-treated with AZA and subsequently cultured with LPS for 48 hours ([Figure 2](#f2-jir-8-193){ref-type="fig"}).

Effect of AZA and LPS treatments on TIMP2 mRNA and protein secretion
--------------------------------------------------------------------

There were no significant differences in *TIMP2* mRNA expression in relation to any treatment in any tissue (data not shown). TIMP2 protein production was significantly decreased in the culture media from placental explants pre-treated with AZA and subsequently cultured with LPS for 48 hours ([Figure 3](#f3-jir-8-193){ref-type="fig"}).

Methylation analysis of *MT1-MMP* promoter region
-------------------------------------------------

*MT1-MMP* promoter was generally hypomethylated across all tissue explants (ranging 4%--6% on average). In addition, no changes in methylation were observed in cultured tissue explants in response to any treatment ([Figure 4](#f4-jir-8-193){ref-type="fig"}).

Chromatin accessibility of treated tissue explants
--------------------------------------------------

Changes in chromatin structure were most evident in villous tissue explants treated with AZA and subsequently exposed to LPS, as shown by the large Ct shift between digested and undigested samples ([Figure 5](#f5-jir-8-193){ref-type="fig"}). Due to sample constraints, chromatin accessibility was only assessed in two villous sample sets, resulting in large variation. While no significant differences were noted, a relative increase was seen in AZA + LPS treatment groups.

Discussion
==========

The present study investigated the response of MT1-MMP, MMP2, and TIMP2 to methylation inhibiting (AZA) and immunomodulating (LPS) treatments in term human gestational tissue explants. We report an increase in MT1-MMP mRNA and protein in response to AZA treatment followed by LPS stimulation. In addition, we examined promoter-specific methylation of the *MT1-MMP* gene.

A previous study reported that *MT1-MMP* mRNA was not increased by LPS treatment in amnion-chorion fetal membrane samples.[@b12-jir-8-193] We observed an increase in MT1-MMP transcription and protein treatment with LPS alone for 24 hours and 48 hours, respectively. When AZA and LPS treatments were combined, we observed a significant increase in *MT1-MMP* mRNA at 24 hours and 48 hours, and in MT1-MMP protein at 48 hours.

TIMP2 protein was decreased in tissues treated with AZA and subsequently stimulated with LPS. Furthermore, although not significant, there is an apparent decrease in TIMP2 protein secretion in tissues treated with LPS only at both time points. This observation is supported by previous studies, which reported a decrease in TIMP2 protein secretion by gestational membranes treated with LPS.[@b25-jir-8-193],[@b26-jir-8-193] Furthermore, decreased *TIMP2* expression has previously been correlated to promoter hypermethylation.[@b27-jir-8-193]

It was interesting to note that although AZA treatment had no effect basally, when combined with LPS, the two treatments appeared to act synergistically to increase MT1-MMP mRNA and protein production. AZA is a methylation-inhibiting agent that is incorporated into the DNA as a cytidine analog and prevents methylation by irreversibly binding to DNA methyltransferases, leading to passive hypomethylation over successive rounds of cell division.[@b28-jir-8-193] Interrogation of the *MT1-MMP* promoter revealed hypomethylation in all term gestational tissues. Furthermore, no change in *MT1-MMP* promoter-specific methylation was observed in explant tissues in response to culture treatments. Thus, as *MT1-MMP* was hypomethylated in the placenta, any AZA-induced changes in methylation were negligible.

It is becoming increasingly apparent that AZA has more far-reaching effects than hypomethylation alone; evidence suggests that AZA is capable of inducing reorganization of the chromatin structure.[@b29-jir-8-193],[@b30-jir-8-193] In this way, AZA may be enhancing the availability of transcriptional regulatory elements in the *MT1-MMP* promoter, or directly interacting with the transcription factors themselves. Preliminary analysis of the chromatin structure of treated explants was assessed using a commercially available kit, which determines the extent of chromatin accessibility to exogenous nucleases. We observed that, for this study, villous explants treated with AZA and LPS had a more open chromatin structure compared to controls, AZA treatments, or LPS treatments alone. This result was represented by a larger shift in qRT-PCR Ct values, calculated as fold enrichment between digested and undigested samples.

A major limitation of this experiment was the low sample number, due to sample constraints. Although significant differences were not noted, the apparent increase observed between treatment groups would be clarified by an increase in sample number. AZA has been shown to reactivate gene expression independent of DNA methylation.[@b31-jir-8-193],[@b32-jir-8-193] AZA can act as an inhibitor of histone methylation, which may account for the reexpression of unmethylated genes.[@b33-jir-8-193] Both hypomethylation of CpG islands and low levels of histone H3 lysine-27 trimethylation are features of transcriptionally active *MT1-MMP* in cancer cell lines.[@b34-jir-8-193]

Co-treatment of human colorectal cancer cell lines with combined AZA and pro-inflammatory cytokines IL-1, IL-6, or TNF-α induces *MMP2* and *MMP9* mRNA to a greater extent than cytokine treatment alone. This cooperative regulation is due to functional interactions between AZA and transcription factors c-Jun and C/EBP.[@b35-jir-8-193] *MT1-MMP* contains a number of regulatory binding sites in its promoter, including several for C/EBP-β; thus, the direct interaction between AZA and transcription factors is a potential mechanism of *MT1-MMP* mRNA regulation in the placenta and fetal membranes in the presence of inflammation.[@b36-jir-8-193] Although we did not observe increased *MMP2* mRNA with combined AZA and LPS treatments, MT1-MMP induction resulted in a significant increase in MMP2 activity in placenta explants after 48 hours.

AZA could also be increasing the expression of toll-like receptors (TLRs) in these tissues, leading to enhanced LPS stimulation of MT1-MMP. TLRs are innate immune receptors that are the principle sensors of bacterial pathogens, and are highly expressed by gestational tissues.[@b37-jir-8-193] TLR type 4 (TLR4) mediates LPS-induced immune responses, and is methylated in human intestinal epithelial cell lines and mice embryonic stem cells.[@b38-jir-8-193],[@b39-jir-8-193] Treatment with AZA restores TLR4 expression in these cells, thereby enhancing LPS responsiveness. In one study, TLR4 reactivation was augmented by combined AZA and TSA (a histone deacetylase inhibitor) treatments, suggesting cooperative control of TLR4 by DNA methylation and histone modifications.[@b38-jir-8-193]

pPROM is associated with increased MMP2 and MT1-MMP concentrations, and decreased TIMP2 protein in fetal membranes and amniotic fluid.[@b13-jir-8-193],[@b16-jir-8-193],[@b18-jir-8-193] In the current study, we report significantly increased MT1-MMP mRNA and protein and MMP2 activity with an associated decrease in TIMP2 protein in placental explants treated with combined AZA and LPS treatments. MT1-MMP and TIMP2 are major mediators of MMP2 activity, and while high concentrations of MT1-MMP facilitate the activation of MMP2, low TIMP2 concentration would result in less inhibition of the activated enzymes.[@b40-jir-8-193] Increased MMP levels in the presence of unchanged or decreased TIMP2 would shift the balance in favour of gelatinase activity, resulting in ECM degradation.

Conclusion
==========

Our results imply that promoter methylation is not directly involved in the regulation of MT1-MMP in human placenta. Rather, alterations in chromatin structure instigated by pharmacologic agents such as AZA could expose regulatory regions in the *MT1-MMP* promoter, allowing for the binding of transcription factors. Furthermore, recent evidence demonstrates the direct interaction between AZA and transcriptional factors in the presence of inflammatory mediators leads to increased *MMP* transcription. Together, this evidence supports a mechanistic link between epigenetic modifications and inflammation in the control of MMP expression. Enhanced MT1-MMP in gestational tissues alongside an associated increase in activation of MMP2 would alter the balance of MMPs and TIMPs, favouring a proteolytic state and thereby making the fetal membranes vulnerable to ECM degradation and subsequent membrane rupture.

We thank staff and patients at Auckland City Hospital for donation and collection of tissue samples. We also thank Dr Devaki De Silva for technical input.

**Disclosure**

The authors report no conflicts of interest in this work.

![MT1-MMP mRNA and protein expression in villous explants.\
**Notes:** (**A**) qRT-PcR was used to detect *MT1-MMP* mRNA expression in tissues treated with/without 5 μg/mL LPS with/without prior 5 μM AZA treatment. *MT1-MMP* mRNA was significantly increased in explants pre-treated with AZA and then cultured with LPS for 24 hours and 48 hours. LPS treatment alone increased *MT1-MMP* mRNA in explants after 48 hours. (**B**) Western blotting was used to detect MT1-MMP protein in tissues treated with/without 5 μg/mL LPS with/without prior 5 μM AZA treatment. MT1-MMP protein was significantly increased in placental explants pre-treated with AZA and then stimulated with LPS for 24 hours and 48 hours and in MT1-MMP protein treated with LPS alone for 24 hours. In (**A**), data are presented as mean fold change in MT1-MMP transcript normalized to *RPLPO* and *RPL13a* compared to time-matched controls (±SEM; n=8 in each group), \**P*\<0.05. In (**B**), data are presented as mean fold change in MT1-MMP protein normalized to β-actin optical density, compared to time-matched controls (±SEM; n=8 in each group); \**P*\<0.05.\
**Abbreviations:** qRT-PcR, quantitative real-time polymerase chain reaction; MT1-MMP, membrane type 1 matrix metalloproteinase; LPS, lipopolysaccharide; AZA, 5-aza-2′-deoxycytidine; *RPLPO*, large ribosomal protein; *RPL13*, ribosomal protein type 13; SEM, standard error of the mean; h, hours; n, number in each group.](jir-8-193Fig1){#f1-jir-8-193}

![Secreted MMP2 activity from villous explants.\
**Notes:** Gelatin zymography was used to assess MMP2 activity in conditioned media from tissue explants treated with/without 5 μg/mL LPS with/without prior 5 μM AZA treatment. Pro-MMP2 activity is shown by white bars; activated MMP2 activity is shown by gray bars. a representative zymogram is shown above the graph. levels of the secreted MMPs were normalized with respect to the total protein content and expressed as a percentage of time-matched controls (mean ± SEM; n=8 in each group); \**P*\<0.05.\
**Abbreviations:** MMPs, matrix metalloproteinases; MMP2, MMP type 2; pro-MMP2, latent MMP2; LPS, lipopolysaccharide; AZA, 5-aza-2′-deoxycytidine; SEM, standard error of the mean; h, hours; n, number in each group.](jir-8-193Fig2){#f2-jir-8-193}

![Secreted TIMP2 protein from villous explants.\
**Notes:** ELISA was used to assess TIMP2 protein in conditioned media from tissue explants treated with/without 5 μg/mL LPS with/without prior 5 μM AZA treatment. levels of secreted TIMP2 were normalized with respect to the total protein content (mean ± SEM; n=8 in each group); \**P*\<0.05.\
**Abbreviations:** TIMP2, tissue inhibitor of metalloproteinase type 2; ELISA, enzyme-linked immunosorbent assay; LPS, lipopolysaccharide; AZA, 5-aza-2′-deoxycytidine; SEM, standard error of the mean; h, hours; n, number in each group.](jir-8-193Fig3){#f3-jir-8-193}

![*MT1-MMP* promoter methylation in villous explants.\
**Notes:** Sequenom™ EpiTyper^®^ MassaRRaY was used to measure methylated cytosine residues (5-mC) within the *MT1-MMP* promoter in tissues treated with 5 μg/mL LPS with/without prior 5 μM AZA treatment. % of 5-Methylcytosine (%5-mC) was calculated from the ratio of mass signals between methylated and nonmethylated DNA in each sample. Data are presented as mean %5-mC across all CpGs ± SEM (n=8).\
**Abbreviations:** MT1-MMP, membrane type 1 matrix metalloproteinase; LPS, lipopolysaccharide; AZA, 5-aza-2′-deoxycytidine; SEM, standard error of the mean; h, hours; n, number in each group.](jir-8-193Fig4){#f4-jir-8-193}

![Chromatin accessibility assay of treated villous explants.\
**Notes:** Chromatin structures of treated villous explants were determined by specific nucleases. DNA in heterochromatin was inaccessible to the nucleases, resulting in insignificant ct shifts between digested and undigested samples, whereas DNA in euchromatin was accessible to nucleases, resulting in a large ct shift shown as fold enrichment. Treatment with combined AZA and LPS resulted in large fold enrichment, signifying the DNA is more open than in the control, AZA alone, or LPS alone treatments. Data are presented as the ratio of amplification efficiency of the Nse-treated DNA sample over that of the No-Nse (control) sample (mean fold enrichment) ± SEM (n=2).\
**Abbreviations:** LPS, lipopolysaccharide; AZA, 5-aza-2′-deoxycytidine; Nse, nuclease; SEM, standard error of the mean; n, number in each group; No-Nse, control samples not treated with nuclease.](jir-8-193Fig5){#f5-jir-8-193}

###### 

gene-specific primers used for qRT-PcR

  Gene        Primer sequence   Amplicon size (bp)       
  ----------- ----------------- ------------------------ -----
  *MMP2*      Sense             5′-ACA GTG CAT CTC AGC   323
                                CCA CAT AGT-3′           
              Antisense         5′-AAG CTC TGA CCT TTC   
                                CAG CAG ACA-3′           
  *MT1-MMP*   Sense             5′-ATC ATG GCA CCC TTT   253
                                TAC CA-3′                
              Antisense         5′-AGC GCT CCT TGA AGA   
                                CAA AC-3′                
  *TIMP2*     Sense             5′-CCC TCC TCG GCA GTG   154
                                TGT-3′                   
              Antisense         5′-GGC TCT TCT TCT GGG   
                                TGG TG-3′                
  *RPLPO*     Sense             5′-AGA AAC TGC TGC CTC   223
                                ATA TCC G-3′             
              Antisense         5′-CCC CTG GAG ATT TTA   
                                GTG GTG A-3′             
  *RPL13a*    Sense             5′-GCC CTA CGA CAA GAA   117
                                AAA GCG-3′               
              Antisense         5′-TAC TTC CAG CCA ACC   
                                TCG TGA-3′               

**Abbreviations:** qRT-PcT, quantitative real-time polymerase chain reaction; *MMP2*, matrix metalloproteinase type 2; *MT1-MMP*, membrane type 1 matrix metalloproteinase; *TIMP2*, tissue inhibitor of metalloproteinase type 2; *RPLPO*, large ribosomal protein; *RPL13*, ribosomal protein type 13; bp, base pairs.

###### 

sequenom™ primers used for *MT1-MMP* promoter methylation analysis

             Primer                                             Start site   Size   GC%     Sequence
  ---------- -------------------------------------------------- ------------ ------ ------- --------------------------------
  Region A   Left                                               71           30     46.67   GGAAAAGAGGAGAAGAGTAAATAGGTATTT
             Right                                              450          27     59.26   AATAAAAACTATCCCCTAAAAAACCCC
             Product size: 380, Tm: 72.0, CpGs in product: 30                               
  Region B   Left                                               377          25     62.50   GGGTTTTGTTTTTAGTTTTGGAAT
             Right                                              1,036        25     50.00   ACTCACAAAAAAAACTTTATATATAC
             Product size: 360, Tm: 72.1, CpGs in product: 38                               

**Abbreviations**: MT1-MMP, membrane type 1 matrix metalloproteinase; GC%, guanine-cytosine percentage; Tm, melting temperature; CpGs, dense region of cytosine and guanine nucleotides.
